CytomX Therapeutics Current Ratio 2014-2021 | CTMX
For a detailed definition, formula and example for Current Ratio, check out our new background page here.
CytomX Therapeutics current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| CytomX Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2021-06-30 |
$0.27B |
$0.09B |
2.90 |
| 2021-03-31 |
$0.40B |
$0.10B |
4.08 |
| 2020-12-31 |
$0.32B |
$0.10B |
3.21 |
| 2020-09-30 |
$0.34B |
$0.10B |
3.34 |
| 2020-06-30 |
$0.37B |
$0.10B |
3.71 |
| 2020-03-31 |
$0.40B |
$0.11B |
3.77 |
| 2019-12-31 |
$0.30B |
$0.09B |
3.54 |
| 2019-09-30 |
$0.34B |
$0.08B |
4.40 |
| 2019-06-30 |
$0.37B |
$0.08B |
4.66 |
| 2019-03-31 |
$0.41B |
$0.10B |
4.21 |
| 2018-12-31 |
$0.45B |
$0.10B |
4.55 |
| 2018-09-30 |
$0.47B |
$0.09B |
5.48 |
| 2018-06-30 |
$0.37B |
$0.08B |
4.41 |
| 2018-03-31 |
$0.37B |
$0.07B |
5.27 |
| 2017-12-31 |
$0.39B |
$0.06B |
6.36 |
| 2017-09-30 |
$0.38B |
$0.07B |
5.28 |
| 2017-06-30 |
$0.34B |
$0.06B |
5.62 |
| 2017-03-31 |
$0.17B |
$0.04B |
4.50 |
| 2016-12-31 |
$0.19B |
$0.04B |
5.26 |
| 2016-09-30 |
$0.18B |
$0.02B |
7.74 |
| 2016-06-30 |
$0.20B |
$0.02B |
8.98 |
| 2016-03-31 |
$0.19B |
$0.02B |
10.85 |
| 2015-12-31 |
$0.19B |
$0.02B |
12.06 |
| 2015-09-30 |
$0.12B |
$0.01B |
8.24 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.00B |
|
0.00 |
| 2014-09-30 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.01B |
$0.00B |
2.22 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.352B |
$0.100B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
